Kolltan Pharmaceuticals to Present at the 11th Annual PEGS - The Essential Protein Engineering Summit

NEW HAVEN, Conn.--()--Kolltan Pharmaceuticals, Inc. today announced that the Company will present preclinical data from its anti-KIT antibody drug conjugate development program at the 11th Annual PEGS - The Essential Protein Engineering Summit, which will take place in Boston, Massachusetts, on May 4-8, 2015.

“KTN0182A, an Anti-KIT, Pyrrolobenzodiazepine (PBD)-Containing Antibody Drug Conjugate (ADC) Demonstrates Potent Antitumor Activity In Vitro and In Vivo Against a Broad Range of Tumor Types.”

The Company will present the following abstract: “KTN0182A, an Anti-KIT, Pyrrolobenzodiazepine (PBD)-Containing Antibody Drug Conjugate (ADC) Demonstrates Potent Antitumor Activity In Vitro and In Vivo Against a Broad Range of Tumor Types.”

Authors: Christine Lubeski1, Gary C. Kemp2, Christina L. von Bulow2, Philip W. Howard2,3, John A. Hartley2,3, Thomas Douville1, Jasmin Wellbrock4, Walter Fiedler4, Sergio Trombetta1, Rich Gedrich1, Yaron Hadari1, Elizabeth M. Mandel-Bausch1.
Kolltan Pharmaceuticals, Inc., New Haven, CT1; Spirogen, London, UK2; ADC Therapeutics Sarl, Epalinges, Switzerland3; Hubertus Wald Tumorzentrum, Department of Oncology-Hematology, Bone Marrow Transplantation and Pneumology, University Cancer Center, Hamburg, Germany4.

About Kolltan Pharmaceuticals

Kolltan, a privately held clinical-stage company, is focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases for the treatment of cancer and other diseases with significant unmet need. Kolltan’s founders and members of its management team have deep expertise and a proven track record in drug discovery, development and commercialization of innovative therapeutics, including drugs targeting kinases. Kolltan is working in close collaboration with the laboratory of Kolltan Co-Founder, Dr. Joseph Schlessinger, as well as the Yale University medical and scientific community. The Company has a broad and novel portfolio of therapeutic biologics targeting multiple receptor tyrosine kinases that are advancing in clinical and preclinical development and are expected to generate multiple near-term milestones.

Contacts

Media Inquiries
Burns McClellan
Justin Jackson, 212-213-0006
jjackson@burnsmc.com
or
Investor Inquiries
Kolltan Pharmaceuticals, Inc.
203-907-0938